Podcasts about EHA

Send us a textH.E. Dr. Ahmed El-Sobky, Ph.D. is Chairman of the Egypt Healthcare Authority ( EHA - https://eha.gov.eg/en/about-eha/ ) and a prominent figure esteemed for his visionary leadership and expertise across clinical and managerial domains. As the Chairman of the EHA since 2020, Dr. El-Sobky has founded the guiding principles of the organization and led transformative measures to enhance healthcare services and accessibility nationwide. Dr. El-Sobky's contributions extend globally as a Member of the UHC2030 Steering Committee and a Governing Council member in the International Hospital Federation, as well as at the Ministry of Health and Population ( MOHP - https://www.mohp.gov.eg/ ), where he supervises critical projects like the Hayah Karima Project ( https://hayakarima.com/en/about-us ) and the Universal Health Insurance Project, leveraging his insights to drive impactful change.Dr. El-Sobky's career in health strategic management started early in 2015 being the youngest assistant, then Deputy Minister of Health and Population for Monitoring and Follow-up affairs, underscoring his dedication to advancing public health locally and globally. Dr. El-Sobky's academic journey is marked by a Ph.D. in Diagnostic Radiology from Menoufia University, Master of Science in Clinical Service Operations from Harvard Medical School, an Executive Diploma in Public-Private Partnership in Healthcare from the Frankfurt School of Finance & Management, and an MBA in Business Administration and Management from Ecole Supérieure Libre des Sciences Commerciales Appliquées.Dr. El-Sobky also chairs the scientific council of the Egyptian board of healthcare management, a position he has held since 2021.#Egypt #AhmedElSobky #EgyptHealthcareAuthority #UniversalHealthInsurance #DiagnosticRadiology #BigData #NewLibraryOfAlexandria #MinistryOfHealthAndPopulation #SustainableDevelopmentGoals #AbdelFattahAlSisi #HepatitisC #HealthcareInformationAndManagementSystemsSociety #Aging #AntimicrobialResistance #Cairo #HayaKarima #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Send us a textWelcome to The Helicopter Podcast, brought to you by Vertical HeliCASTS!Host Halsey Schider engages in a compelling conversation with Fredrik Kämpfe, chair of the European Helicopter Association (EHA). Fredrik shares insights into the collaborative efforts between EHA and the European Rotors event, highlighting their joint mission to advocate for and advance the European helicopter industry.Fredrik outlines his role within EHA, emphasizing the organization's dedication to representing the helicopter community across 13 European countries. He discusses EHA's proactive engagement with operators and the European Union Aviation Safety Agency (EASA) to address key industry challenges, including regulatory developments, safety enhancements, and sustainability initiatives. Under Fredrik's leadership, EHA has been instrumental in organizing events like European Rotors, which serve as platforms for industry stakeholders to collaborate, share knowledge, and showcase innovations. These efforts aim to foster a unified and progressive rotorcraft community in Europe. Tune in to this insightful episode to learn more about EHA's initiatives and Fredrik's vision for the future of the European helicopter industry.Thank you to our sponsors Vertical Aviation International, Robinson Helicopters and Sellacopter.

In this episode of Hema Now, Dr. Jonathan Sackier welcomes Professor Antonio Almeida, a leader in hematology and the 2024 President of the EHA. They delve into the highlights from this year's EHA Congress, discuss the founding of the Católica Medical School, and explore the transformative role of AI in healthcare.   Timestamps:  (00:00) -Introduction  (01:40) -Reflection on the EHA 2024 Congress  (06:10) -Approaches for future congresses  (10:30) -Proudest accomplishments and EHA education initiatives   (17:00) -Reflections on the treatment landscape of blood-related conditions   (26:00) -Importance of registries in uncovering more about these diseases  (30:10) -Potential of AI in hematology  (32:50) -Role of public policy in shaping the future of hematology  (37:00) -What drove Antonio to found a medical school  (40:00) -Antonio's three wishes 

Legendary Melvins drummer Dale Crover is back on the show and this time he's bringing some friends! AAL and EHA of Low Flying Hawks are making their podcast debut to celebrate two new albums: Low Flying Hawks' Makebelieve coming out October 25 and Dale Crover's awesome new solo album Glossolalia, out now! In our chat, we talk about the writing process for the latest LFH album, the residual affects of the pandemic that still linger for artists, taking two years to create the album this time around, and the idea that mystique brought something tangible to music and artists. Then we sequel over to Dale Crover's awesome guests that he got on his latest solo record, the story of how he got Tom Waits to say “yes” to being a part of the title track, him opening as a DJ on the upcoming Red Kross European run, and the pros of modern music recording compared to the time crunch the Melvins had early on. Petar and Sylvia discuss Kerry King's answer in who he thinks can portray him in a Slayer biopic film, Sick New World coming back to Vegas and bringing an Acid Bath reunion with it, just accepting their would never be an Acid Bath reunion years ago to our surprise, Jake E. Lee getting shot while walking his dog, and Deftones setting a record with there demo tape on Discogs. Song: Low Flying Hawks “Suspension of Disbelief” Song: Low Flying Hawks “Out for Blood” Song: Dale Crover “I Quit” Featuring Kim Thayil of Soundgarden Learn more about your ad choices. Visit podcastchoices.com/adchoices

How can you optimize the treatment pathway for relapsed or refractory chronic lymphocytic leukemia (CLL)? Join the experts as they delve into the latest updates from EHA 2024.    Credit available for this activity expires: 07/31/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001409 ?ecd=bdc_podcast_libsyn_mscpedu

Today's VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH,... The post Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs appeared first on VJHemOnc.

The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the... The post The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 appeared first on VJHemOnc.

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trialEfficacy of pacritinib in patients with MF who have both thrombocytopenia and anemiaUpdated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MFImpact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegalyProgression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST studyJAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia veraPhase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MFPatient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib Program faculty:Brady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, Illinois Resources:To download the slides associated with this podcast discussion, please visit the program page.

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AMLA retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapyFinal 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 studyFirst-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1 Program faculty:Eunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkCourtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasResources:To download the slides associated with this podcast discussion, please visit the program page:https://bit.ly/4bvJGij

BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted... The post Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024 appeared first on VJHemOnc.

La Dra. Nidia Zapata, hematóloga en la Ciudad de México, México, nos comenta sobre lo más destacado presentado en los Congresos de ASCO y EHA del presente año, resaltando los siguientes estudios: Congreso ASCO 2024: Linfomas de células B: • EPCORE NHL-1 Mieloma múltiple: • IMROZ Leucemia linfocítica crónica: • Poster 7050 • CELESTIAL-TNCLL Congreso EHA 2024: Leucemia mieloide aguda: • AUGMENT-101 Leucemia linfocítica aguda: • HOVON- 146 Mieloma múltiple: • Cassiopeia Linfoma difuso de células b grande: • EPCORE NHL-5 Leucemia mieloide crónica: • OPTIC Fecha de grabación: 21 de junio de 2024 Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

Show notes 1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships 2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology 3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions 4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers 5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars 6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars 7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability 8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1.      STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCLhttps://library.ehaweb.org/eha/2024/eha2024-congress/4136516 2.     Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):https://library.ehaweb.org/eha/2024/eha2024-congress/422343 3.     3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740 4.     ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515 5.     HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext 6.     Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268 7.      Single-agent epcoritamab in Richter's transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the  EHA 2024 Congress including:COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDSReal-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practicePhase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDSPhase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysis Program faculty:Courtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasBrady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, IllinoisEunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkResources:To download the slides associated with this podcast discussion, please visit the program page.

On this week's Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Eric Schmidt, Sam Fazeli, Bruce Booth and Grace Colon discuss the big news of the week including the FDA granting a landmark expanded approval for Sarepta's Elevidys for patients with Duchenne Muscular Dystrophy. The hosts share their varying opinions on whether the expanded approval was the right decision. The group also engages in a few discussion topics around management, including the “everything is awesome CEO” and the best and worst practices for managing a board. With multiple companies dealing with a stock drop this week (Cabaletta Bio, Kyverna Therapeutics, Taysha Gene Therapies, Aerovate Therapeutics, Ovid Therapeutics), the hosts discuss the different issues these pose for management teams and how to deal with market reactions. The group also shares thoughts on the 2024 class of IPOs, EHA 2024 highlights, BioNTech's clinical hold on its early-stage cancer drug study, and much more. This episode aired on June 21, 2024.

In this podcast episode, three of Canada's top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada.  Our Guests:Dr. Versha Banerji from Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba chairs the meeting. Dr. Banerji is joined by Dr Sarit Assouline, from the Jewish General Hospital in Montreal, Quebec and Dr. Christopher Hillis, from McMaster University in Hamilton, Ontario. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/)

In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter's... The post Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more appeared first on VJHemOnc.

Guest speaker “Angus” Shipo Xie of Hankun Law joins Brian Yang to discuss new overseas data transfer rules, while Dexter Yan explains China biotechs' Hutchmed, Jiangsu Hengrui and Innovbent Bio's clinical data readouts at the recent EHA and ADA annual meetings. https://scrip.citeline.com/SC150487/China-Biotech-Podcast-EHAADA Playlist: https://soundcloud.com/citelinesounds/sets/chinese-language-biopharma

Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the EHA 2024 Hybrid Congress, June 13-16, Madrid, Spain.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025FACULTYCindy Neunert, MDAssociate Professor of PediatricsColumbia University Irving Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcasts-in-pediatric-itp-advancements-in-pediatric-itp-management-insights-from-eha-2024

In this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024! How did we get to our current standard of care in APL? How and why did the PETHEMA, GIMEMA, UK MRC, and other cooperative group regimens evolve over time into what they are today? And importantly, is the APOLLO control arm (no arsenic!), ok? Tune in to find out!

Müstilistele ja vahel ka maistele teemadele pühendunud saates „Puuduta mind“ on seekord külas nõid Eha ehk selgeltnägijate seas tuntud ka kui Witch Eha. Ta on tegelenud esoteerikaga juba neli aastakümmet ning aidanud inimestel leida lahendusi nende probleemidele, kasutades selleks iidseid tarokaarte, ruune või pendlit. Seekord teemegi nende vidinate õigeks kasutamiseks korraliku koolituse. Enamasti tullakse Witch Eha vastuvõtule alles siis, kui inimeste elus on juba toimunud ebameeldivad sündmused, ning otsitakse abi tagajärgede likvideerimiseks. Nõid Eha sõnul on palju tõhusam probleemi ennetada juba eos. Parim võimalus selleks on ennast laadida ja kaitsta ruunimärkidega, olla seeläbi kaitstud kõige halva ja negatiivse eest ning lõpuks saada seda, millest oled eluaeg unistanud. Saadet juhivad Anu Saagim ja Maria Baydar.

It's becoming more and more difficult to share the gospel in India. However, one pathway to get the truth of God's Word to people on the ground is to meet their physical needs. This week on Missions Today, we meet one of the men leading an effort to support hospitals and clinics across India that are not only serving people but sharing the love of Christ on a daily basis. That's this weekend on Missions Today! For more information on our guest this week and his work, please check out the links below: Robb Hansen Emmanuel Hospital Association USA #medical #doctors #hospitals #clinics #india #northernindia #missions #medicalmissions #robbhansen #EHA #compassion #medicalcare

Clara Camaschella"La donna del ferro"Neos Edizioniwww.neosedizioni.it“Sono considerata una delle rare donne che hanno fatto carriera in medicina alla fine degli anni Novanta”.Così inizia il racconto di Clara Camaschella. Dalla Valsesia degli anni Sessanta alla Facoltà di Medicina di Torino negli anni Settanta e, dopo una borsa di studio oltreoceano, una lunga, prestigiosa, ma molto faticosa e complessa carriera scientifica alla scoperta dei misteri del sangue e… del ferro. L'autobiografia di Clara Camaschella è un racconto di vita e lavoro dove, con ironia e leggerezza e un linguaggio schietto ma rigoroso, si affrontano anche tematiche complesse (il superamento di un handicap, la malattia), in particolare le difficoltà delle donne ad affermarsi negli ambienti universitari a causa del maschilismo. Clara Camaschella cresce in un mondo provinciale fatto di religione, suore, colonie estive e Azione Cattolica. Al liceo confida al suo diario le paure e la voglia di prendere in mano il proprio futuro La scelta della Medicina, all'Università di Torino, le fa scoprire un mondo nuovo i cui orizzonti si amplieranno ulteriormente durante uno stage negli Stati Uniti condiviso con colui che diventerà suo marito. Nel 1991 all'Ospedale San Luigi di Orbassano, secondo polo didattico dell'Università di Torino, inizia ad occuparsi della genetica molecolare dell'emocromatosi (“È stato l'inizio di un'avventura molto bella che ha portato a capire la fisiologia del metabolismo del ferro e la sua sregolazione nelle malattie”). La sua carriera, prima a Torino poi a Milano, sarà una corsa ad ostacoli (“Quando il Consiglio di Facoltà si restringeva ai soli professori ordinari noi donne rappresentavamo sempre uno sparuto gruppetto, al san Raffaele ci si poteva contare sulle dita di una mano!). Ordinaria di Medicina Interna all'Università di Torino, dal 2004 ha ricoperto lo stesso ruolo all'Università Vita Salute San Raffaele di Milano, passando da un'attività prevalentemente clinica alla ricerca scientifica. “L'importante è chiedere molto a noi stessi indipendentemente dai risultati”: il mantra che le è stato ripetuto più volte è diventato regola di vita, consentendole di diventare figura di prestigio in ambito medico scientifico internazionale per le sue ricerche sul metabolismo e le patologie del ferro. Ha coordinato con successo due gruppi di ricerca, prima a Torino, poi a Milano. Grazie ai risultati e alle collaborazioni ha ottenuto premi prestigiosi, è stata Presidente della Società Internazionale per lo studio del ferro in Biologia e Medicina (BioIron), membro del board di riviste internazionali e di società scientifiche sia in Europa, sia negli Stati Uniti. “Nel caso di cariche elettive ho battuto uomini che consideravo molto più capaci di me, purtroppo sempre con il sospetto di aver vinto solo perché donna”. Clara Camaschella, nata a Varallo nel 1948, dopo la maturità classica si è laureata in Medicina a Torino e poi specializzata in Medicina Interna e in Ematologia. Una carriera legata a Torino dove ha svolto attività clinica alle Molinette e al San Luigi di Orbassano. Ordinaria di Medicina Interna dal 2000, dal 2004 ha ricoperto lo stesso ruolo all'Università Vita Salute San Raffaele di Milano. Responsabile di una Unità di Ricerca sul metabolismo del ferro è stata vicedirettrice della Divisione Genetica e Biologia Cellulare dell'IRCCS Ospedale San Raffaele. Autrice di duecentottanta pubblicazioni scientifiche e collaborazioni a testi internazionali, ha fatto parte del Board della società di Ematologia americana ASH e dell'europea EHA e Presidente della Società Internazionale per lo studio del ferro BioIron. Ha ricevuto premi scientifici come la Ham Wasserman lecture e il Jean Bernard life time achievement award Sposata con Federico Caligaris Cappio, dopo molti anni a Torino, ora vive a San Felice di Segrate (Milano). IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

After a 5 minute score by Nathaniel Finch, David Eha recaps some college basketball action. Eha covers Ball State for the Ball State Network, and the Cardinals won 76-67 over Western Michigan. Tanner Camp of The Region Radio Sports Network joins Coach to talk about Marquette Catholic's win over Triton. Kurt Darling of Nine Star TV calls in to recap some more boys basketball. Darling gives a rundown of the Tipton 60-46 win over Shenandoah. Dave Sockel of Southern Indiana Sports Productions turns the focus back on Girls' Sectionals. He covered the Bedford North Lawrence 43-39 win over Jennings County. Kenny Kramer from LVH1 calls in and recaps LaVille's 47-37 win over North Judson. Andrew Smith of the New Pal Radio Network joins Coach to talk about Mt. Vernon's 48-39 win over New Palestine. Len Clark of Irish101.com calls to recap Notre Dame's rough loss to Pitt. The final score for that game was 70-60. Coach Kyle Brummett of Wabash joins to talk about his team's 89-81 win over Denison University. See omnystudio.com/listener for privacy information.

Robb Hansen is in-studio to talk with us about the Emmanuel Hospital Association, a medical ministry that serves the marginalized in North India. Rob voluntarily leads EHA (USA) which exists to support the work of EHA in India through a growing network of churches and individuals who partner through the U.S. office to provide prayer and financial support. See omnystudio.com/listener for privacy information.

Jonathan is joined by Elizabeth Macintyre, President-Elect and Board Member of the Biomedical Alliance, Europe; and Past President of the European Haematology Association (EHA). The pair delve into the world of haematology, focusing on Macintyre's research towards equal access, haematological diagnostics, and her presidency during the COVID-19 pandemic.  Use the following timestamps to navigate the content in this episode:  (00:00)-Introduction  (01:39)-Macintyre's route into medicine   (04:13)-Haematology in Europe, and leading the EHA   (08:30)-Diagnostics in haematological malignancies  (10:18)-Changes to congress following COVID-19  (14:12)-Coffee conversations   (15:36)-Madrid 2024  (18:42)-Jonathan speaks French   (24:07)-Medical politics and economics  (30:00)-Accessing new treatments   (35:43)-Three wishes for the future of healthcare  

Lubię, gdy w naszym podcaście o grach planszowych Crash Board, jest tłoczno od gości, ale też od gier. Tym razem wraz z Anią z GryfGra, Magdą i Moniką z Piątku z planszówką oraz Ewą z Baba Jaga gra i czyta rozmawiamy o serii Spór o Bór od wydawnictwa Muduko. W tej serii wydano już 5 gier, ich autorem jest Reiner Knizia, a ilustruje je Piotr Sokołowski. Omawiamy każdą grę od Sporu o Bór po Sojusz na już i nie tylko... Ale to nie wszystko, zaproszonych gości czeka podczas tego odcinka niespodzianka!Ale ciii, nic nie zdradzę przesłuchajcie sami, mam nadzieję, że Wy również będziecie zaskoczeni.Ten odcinek podcastu o grach planszowych Crash Board, nagrywany był pod koniec września 2023 r. z założeniem puszczenia w październiku w okolicach urodzin podcastu. Niestety zaburzenia w polu magnetycznym Ziemi i kilka innych mniej lub bardziej wpływających na rzeczywistość drobiazgów spowodowały, że tym odcinkiem żegnamy rok 2023.Jedynie 3 miesiące obsuwy, ale nie licząc kilku nawiązań do urodzin, to w sumie wcale się nie zestarzał.Ja jestem Maciek i od ponad dekady gram w nowoczesne gry planszowe. Nasze zbiory to ponad trzysta gier i ta liczba nadal rośnie.Hania to moja 11-letnia córka, miłośniczka zwierząt, marzycielka, uwielbia rysować, rzeźbić oraz lepić i kolekcjonuje wszystko co się da – po tatusiu. :)Razem tworzymy zgrany zespół, który nie zawsze się zgadza, ale zawsze dobrze się bawi nad planszą.Ewa (Baba Jaga gra i czyta) zaraża innych swoją pasją do gier planszowych, do książek i komiksów. To kobieta pracująca, żadnej pracy się nie boi, pracuje w bibliotece, wynajmuje domek, maluje, nagrywa podcast EHA planszówek i promuje granie w planszówki na każdym kroku, a jej pasją jest fotografia. A jeśli tego Wam mało to właśnie ogłosiła, że jej ilustracje pojawią się na nowej grze od wydawnictwa Egmont.Ania (GryfGra) od lat robi wspaniałe zdjęcia planszówek i wraz z mężem dostarcza świetne recenzje gier planszowych.Magda i Monika (Piątek z planszówką) to zapaleńcy, choć są zupełnie inne, razem tworzą energetyczny duet planszowych pasjonatów.Czy to już wszyscy goście z tego odcinka?Tak, być może, nie wiem, przekonajcie się sami. Jeśli macie uwagi co do podcastu lub chcecie się czymś z nami podzielić, piszcie na: crashboardpodcast@gmail.com.Nasz profil znajdziecie na Facebooku i Instagramie wpisując w wyszukiwaniu: Crash Board.Oprócz podcastu, możecie przeczytać recenzje gier na naszym blogu ZnadPlanszy.-MaciekPS. Część omawianych gier otrzymaliśmy od wydawcy w ramach współpracy recenzenckiej. Więcej o grach z serii Spór o Bór dowiecie się z serwisu Planszeo.

"Gry do świątecznego grania.”Cześć, witamy Was tuż przed świętami. Zebraliśmy się z Ewą z kanału Baba Jaga gra i czyta, by nagrać dla Was świąteczny odcinek naszej serii Board Witch Project. To wszystko w ramach podcastu o grach planszowych Crash Board. Staramy się zawsze opowiadać o grach wg własnych czasami dziwnych kryteriów. Tym razem opowiemy o fajnych grach wg Nas do rodzinnego grania podczas świąt.Będą gry graficznie kojarzące się ze świętami, ale także takie idealne, gdy jesteśmy najedzeni i niewiele się już chce. W naszym zestawieniu znajdzie się coś dla wielbicieli magii, poszukiwaczy przygód, imprezowiczów, detektywów, dzieciaków, kierowców wyścigowych i tych co lubią gry na refleks. Przygotowaliśmy ponad 20 gier do grania między kolejną porcją pierogów, a filmem z Hugh Grantem.Nasz podcast o grach planszowych Crash Board, jest inny, ponieważ opowiadamy o grach z perspektywy taty gracza i jego córki, a teraz jeszcze z perspektywy czarownicy mieszkającej w lesie.Ja jestem Maciek i od ponad dekady gram w nowoczesne gry planszowe. Nasze zbiory to ponad trzysta gier i ta liczba nadal rośnie.Hania to moja 11-letnia córka, miłośniczka zwierząt, marzycielka, uwielbia rysować, rzeźbić oraz lepić i kolekcjonuje wszystko co się da – po tatusiu. :)Razem tworzymy zgrany zespół, który nie zawsze się zgadza, ale zawsze dobrze się bawi nad planszą.Ewa zaraża innych swoją pasją do gier planszowych, do książek i komiksów. To kobieta pracująca, żadnej pracy się nie boi, pracuje w bibliotece, wynajmuje domek, maluje, nagrywa podcast EHA planszówek i promuje granie w planszówki na każdym kroku, a jej pasją jest fotografia. A jeśli tego Wam mało to właśnie ogłosiła, że jej ilustracje pojawią się na nowej grze od wydawnictwa Egmont.Jeśli macie uwagi co do podcastu lub chcecie się czymś z nami podzielić, piszcie na: crashboardpodcast@gmail.com.Nasz profil znajdziecie na Facebooku i Instagramie wpisując w wyszukiwaniu: Crash Board.Oprócz podcastu, możecie przeczytać recenzje gier na naszym blogu ZnadPlanszy.-MaciekPS. Część omawianych gier otrzymaliśmy od wydawców w ramach współpracy recenzenckiej. Ale nie miało to wpływu, na nasze opinie.

Jonathan is joined by António Almeida, President of the European Hematology Association (EHA); and Professor and Director of the Clinical Haematology Service, Hospital da Luz, Lisbon, Portugal, to discuss his highlights since becoming EHA President. The pair cover the three pillars of EHA, the anticipated topics for the 2024 congress, and how Almeida has implemented a brand-new medical school, as well as much more.    Use the following timestamps to navigate the content in this episode: (00.00)-Introduction (01:55)-Almeida's new medical school (03:35)-EHA Master Class peer-based learning and modern medical education (09:00)-Presidential highlights  (11:50)-EHA's three pillars in the coming year (16:05)-EHA 2024 in Madrid (20:15)-Research in myeloproliferative and myelodysplastic syndromes (23:00)-Clinical trial updates in myelodysplastic syndromes and chronic myeloid leukaemia (26:50)-Changes over the course of Almeida's career (31:30)-Treatment advances on the horizon (32:50)-CRISPR to treat sickle cell disease and β-thalassaemia (36:30)-Three wishes for the future of healthcare 

In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl.Here are the shownotes:1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutationhttps://www.nejm.org/doi/full/10.1056/nejmoa1614359 3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext 4. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupshttps://ashpublications.org/blood/article/127/12/1551/35035/Benefit-of-high-dose-daunorubicin-in-AML-induction 5. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.2017.72.8618?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 6. Phase 3 trial of gilteritinib plus azacitidine vs. azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyhttps://ashpublications.org/blood/article/140/17/1845/486088/Phase-3-trial-of-gilteritinib-plus-azacitidine-vs 7. ADMIRAL: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AMLhttps://www.nejm.org/doi/full/10.1056/nejmoa1902688 8. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.22.00602?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 9. Levis MJ, Hamadani M, Logan B, et al: BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023 Hybrid Congress. Abstract LB2711. Presented June 11, 2023. 10. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30455-1/fulltext?dgcid=raven_jbs_etoc_email

Welcome to a new episode of the Natural Beauty Podcast, where the host Satu Mäkinen talks with Eha Urbsalu – the founder of the award-nominated Estonian natural cosmetics brand Viking Beauty Secrets.In the episode, Eha shares more about the Exfoliating Face Scrub, which is nominated for the European Natural Beauty Awards this year 2023.We also talk about how Viking Beauty Secrets is making efforts towards a cleaner environment and how Eha thinks the cosmetics industry will look like going into the future.You can follow Viking Beauty Secrets on social media, such as Instagram, and learn more about the brand's products on their website at vikingbeauty.eu.Natural Beauty Podcast is powered by the Nordic & European Natural Beauty Awards. By following the Natural Beauty Podcast, you will stay updated with the highlights from both awards.To learn more about the European Natural Beauty Awards, such as about the freshly nominated European edition cosmetics, jump to europeannaturalbeautyawards.com.Get to know all the previously awarded cosmetics of the Nordic Natural Beauty Awards, and learn more about the Nordic edition at nordicnaturalbeautyawards.com.Join the conversation on our social media channels; Nordic Natural Beauty journey on Instagram, European Natural Beauty journey on Instagram, and all the initiatives' common journey on LinkedIn.To stay updated on all news, make sure you have subscribed to this podcast and Natural Beauty Awards's newsletter.Disclaimer: This podcast is for entertaining and educational purposes only. If you have health concerns, seek professional medical advice.(Music by Wataboi from Pixabay.)

Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will include the expanding world of bispecific antibodies that include one FDA-approved drug and anticipated approvals for two new bispecific antibodies. He will also discuss exciting results from CAR T cinical trials,  CAR T newcomers, sequencing preferences, BCMA targeted therapies, new therapy targets in myeloma, MRD advances, blood-based testing, clinical trials end points and more.  Thanks to our episode sponsor, Karyopharm.

Drs. Masarova and Mesa discuss myelofibrosis data presented during the 2023 annual meeting of the European Hematology Association.

The Trader Joe's recall situation has garnered significant attention in the past few weeks, as the popular retail chain declared three different product recalls during the last week of July. In this episode of the Xtalks Food Podcast, Sydney talks about the details of the recall, which has raised some eyebrows with food safety. Trader Joe's, in a statement to Vox, called the series of recalls “a coincidence.” Yet, Melvin Kramer, President of the EHA environmental and public health consulting group, suggests another theory. The unique appeal of Trader Joe's to consumers lies in its blend of global and local foods produced by small-scale makers. This variety may increase Trader Joe's recall risk compared to stores sourcing from large-scale manufacturers. Trader Joe's has gained a cult-like following for selling a variety of local specialty foods and crafting engaging narratives about its brands; however, the recent increase in Trader Joe's recall from once or twice a month to three times in a week is alarming. The team talks about the lack of oversight from federal authorities like the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) and wonder whether consumers are partially to blame for high demand.Also in this episode, Sydney reviews Netflix's new food safety documentary, “Poisoned: The Dirty Truth About Your Food.” The objective of the documentary is not to dictate what foods the audience should avoid due to health concerns or to debunk myths about so-called healthy foods. Rather, its primary focus is to shed light on the negligent food safety practices employed by various companies and federal authorities. The film unpacks a variety of food safety issues, starting with the notorious E. coli outbreak between 1992 and 1993 that claimed the lives of four children who had eaten contaminated burgers from the fast-food chain Jack in the Box. The film also profiled Kenneth Kendrick, a former plant manager at Peanut Corporation of America who blew the whistle on his boss, corporation owner Stewart Parnell, for tampering with inspection records to ship out contaminated nuts. The narrative unfolds through several viewpoints, including those of food industry attorneys, politicians, regulators, scientists, victims' parents and implicated businesses. The team praises the documentary for shedding light on several important but overlooked food safety issues in the US.Read the full article here:Trader Joe's Recall 2023: Multiple Products Under the MicroscopeNew Netflix Food Documentary Exposes America's Faulty Food Safety SystemFor more food and beverage industry content, visit the Xtalks Vitals homepage.Follow Us on Social Media Twitter: @XtalksFood Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLLSEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLLCAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphomaPhase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLLBRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLLPresenters:Catherine C. Coombs, MD, MSAssociate Clinical ProfessorDivision of Hematology/Oncology, Department of MedicineUCI HealthOrange, CaliforniaToby Eyre, MBChB, MDHonorary Senior LecturerHematology and CancerUniversity of OxfordConsultant HematologistDepartment of HematologyHematology and Cancer Centre, Oxford University Hospitals NHS Foundation TrustOxford, United Kingdom 

Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent... The post CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors appeared first on VJHemOnc.

Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent... The post CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors appeared first on VJHemOnc.

This week we're joined by Gillian Campbell, the Communications and Public Affairs Lead at Existing Homes Alliance Scotland, a professional with a wealth of experience in the housing sector.Gillian has been involved in some really interesting work around influencing government policy around their retrofit strategy. In particular, their research has revealed insights that are relevant to anyone in the retrofit sector: from the need for good messaging, to the importance of timing in using it, and the fundamental need for frameworks that support and enable consumers to act. Whether the audience is a homeowner or asset manage, in Scotland or North America, the lessons are largely relevant to all. Notes from the episodeThe Existing Homes Alliance ScotlandBuilding blocks for successful customer journeys to net zero homes – EHA Policy PaperOwning the Future: a framework of regulations for decarbonising owner-occupied homes in Scotland – Report for the EHA by Dr Catrin Maby and Louise SunderlandAffordable Warmth – Next steps for clean heat in Scotland – Report by WWF ScotlandThe Novoville platform we mentioned**SOME SELF-PROMOTING CALLS TO ACTION**We don't actually earn anything from this, and it's quite a lot of work, so we have to promote the day jobs.Zero Ambitions Partners email address - zap@eiux.agencySubscribe and advertise with Passive House Plus (UK edition here too)Join ACANJoin the AECB Join the IGBCListen to Accelerate to Zero, Sara's podcast produced at BE-ST, on Apple or Spotify Email Alex and Dan about websites, branding, and communications - zap@eiux.agency; Everything is User Experience**END OF SELF-PROMOTING CALLS TO ACTION**

In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients... The post Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice appeared first on VJHemOnc.

In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients... The post Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice appeared first on VJHemOnc.

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes:1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf92. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/3. Clinical trials of GPRC5D CAR T-cell therapy in multiple myeloma:a) MCARH109 (MSKCC Trial): https://pubmed.ncbi.nlm.nih.gov/36170501/b) POLARIS Trial: https://pubmed.ncbi.nlm.nih.gov/36725117/3. Phase 1 UNIVERSAL trial of ALLO-715 in Multiple Myeloma: https://pubmed.ncbi.nlm.nih.gov/36690811/4. Anti BCMA/CD19 CAR T-cells with IMiD maintenance therapy in myeloma: https://pubmed.ncbi.nlm.nih.gov/36413381/ 

The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and... The post Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management appeared first on VJHemOnc.

The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and... The post Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management appeared first on VJHemOnc.

Frontline systems: Nisuwa https://zkillboard.com/system/30045352/ Tannolen https://zkillboard.com/system/30002812/ Alparena https://zkillboard.com/system/30003850/ Nennamaila https://zkillboard.com/system/30045344/ Hasmajaala https://zkillboard.com/system/30002806/ Aldranette https://zkillboard.com/system/30003837/ Pynekastoh https://zkillboard.com/system/30045353/ Oicx https://zkillboard.com/system/30003838/ Eha https://zkillboard.com/system/30045319/ Oinasiken https://zkillboard.com/system/30045347/ Sujarento https://zkillboard.com/system/30002809/ Evaulon https://zkillboard.com/system/30003839/ Nagamanen https://zkillboard.com/system/30002807/ Onatoh https://zkillboard.com/system/30002811/ https://www.eveonline.com/news/view/introducing-factional-warfare-leaderboards https://universe.eveonline.com/new-eden-news/galactic-hour-news-roundup-shipcaster-technology-leak-stellar-transmuters Broadcasted live on Twitch -- Watch live at https://www.twitch.tv/guldanagestories --- Send in a voice message: https://podcasters.spotify.com/pod/show/federationfrontlinereport/message

El 4 de febrero se celebra el Día Mundial contra el Cáncer, una fecha que recuerda la necesidad de fomentar la prevención y sensibilización para reducir las muertes prevenibles e incentivar la toma de decisiones. La cardio-oncología intenta dar respuesta a las necesidades asistenciales de los pacientes oncológicos, especialmente de aquellos que se someten a tratamientos antitumorales. En este episodio, los expertos Teresa López Fernández (Cardiología, SEC), Raúl Córdoba Mascuñano (Hematología, EHA) y Karen Ramírez Cervantes (Medicina Preventiva, AECC) destacan la importancia de un abordaje multidisciplinar en el paciente oncológico, que involucra a diferentes especialidades y otras formas de asistencia durante la enfermedad.

Study showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact. https://ashpublications.org/blood/article/136/7/823/460669/Does-time-from-diagnosis-to-treatment-affect-the RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy for AML https://www.nejm.org/doi/full/10.1056/nejmoa1614359 Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the European LeukemiaNet (ELN) https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022 ASH 2022 abstract presenting Daunorubicin 60 Vs 90 mg/m2 https://ash.confex.com/ash/2022/webprogram/Paper157126.html ALFA-0701. The addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute myeloid leukemiahttps://www.thelancet.com/article/S0140-6736(12)60485-1/fulltext Quizartinib data presented at EHA 2022 https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Amarker%3D1749%2Afeatured%3D17676 International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemiashttps://ashpublications.org/blood/article/140/11/1200/485730/International-Consensus-Classification-of-Myeloid The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasmshttps://www.nature.com/articles/s41375-022-01613-1  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.2017.77.6112?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed  Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remissionhttps://www.nejm.org/doi/full/10.1056/NEJMoa2004444

While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years.... The post Myeloma treatment updates from EHA 2022 appeared first on VJHemOnc.

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLLFLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy durationBRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCLPresenters:Othman Al-Sawaf, MDFaculty of MedicineUniversity Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, GermanyVisiting ScientistThe Francis Crick InstituteUCL Cancer Institute, University College London London, United KingdomLydia Scarfò, MDLaboratory of B-Cell Neoplasia, Division of Experimental OncologyStrategic Research Program on CLLUniversità Vita Salute San Raffaele and IRCCS Ospedale San RaffaeleMilano, ItalyLink to full program:https://bit.ly/3OQ6634

Myeloma advancements are happening quickly. Learn more from Paul Richardson, MD of the Dana Farber Cancer Institute about the latest findings from two key summer conferences.  Thanks to our episode sponsor, Glaxo Smith Kline

這集感謝網友幫我做筆記，讓我很快的可以整理好內容！大感謝！　 1.翠翠：疫苗亂象：朋友身為醫護剛打完，但當義消的爸媽也打到了，比醫護第一線人員還早打到，在北部基隆那邊。 2.因為 WHO 訂不出免疫橋接標準，所以用 AZ 跟國產比較，但還有很多空間可以調整，如果要用部桃的兩百人當作比較標準，會不會太鬆？ 04b：一切的問題就是這是我們自己訂的，國際沒說可以這樣做，方向是這樣，細節沒訂出來，但因為我們事到臨頭，只好自己訂出來。會不會太鬆或太緊也不是我說的算，重點就是沒有標準，一定會被批評，爭議會繼續下去。解決方式就是有人願意打之後，台灣還是有疫情，打的速度很快，會在社區裡看到有人得病有人沒有，就可以算出現實生活中的保護力，最後可能會走這種狀況。 3.黃醫師：EHA 討論：1. 有研究做細胞治療的病人，三個月後打 BNT 疫苗，觀察安全性，雖然只有收八十人，看起來是可以接受，有副作用但可以治療。血液科如果有這樣的狀況還是可以施打。2. 歐洲登錄過去血液科感染的病人，第一波死亡率 40%，第二波 20 幾 %，某些診斷，例如急性骨髓性白血病、骨髓分化不良症候群特別高，打去甲基化藥物的病人死亡率高達 50%。3. 義大利前瞻性研究收了38 個病人，得了新冠之後抗體生成狀況，大概八成有抗體，但持續不久，一下子就消失，打莫須瘤的病人，抗體基本上不會出現，現在有針對 B 細胞的治療。會繼續再看下去，血液科的病人還是要打疫苗，但是要定期施打，維持好一點的抗體。現在收有打疫苗的病人 之後可能就會知道哪些疫苗值不，得打或多久打一次，血液科病人比較複雜。 4.Kiki：這兩天開始要打 80 幾歲的疫苗，想說外婆應該會去打疫苗，也有告知自己有打疫苗，但同住的親戚說不能打，怕會有副作用，另外如果是去醫院打更危險，不希望外婆出去接觸人群，又說以後疫苗很多，不差這時間打，但這樣就沒有保護力。可是同住者會進進出出怕感染。（住在新竹縣） 04b：雙北遇到病毒的機率較高。出門一趟遇到病毒的機率沒這麼高，通常疫苗副作用都很輕微，英國就是從最老的往下打，老人 AZ 的副作用比年輕人少兩三成，不會因為副作用再帶去醫院，頂多燒一天就這樣，不會要去醫院。現在還有獨居老人，暫時躲著不出門說得， 但是跟年輕人一起住的最危險。 5.Jamie：美國不是沒有核准 AZ？怎麼有無症狀的研究？ 04b：因為是在英國、南非、巴西，主要在英國有做臨床實驗，後來有在美國做。Novavax 就是在美國做比較久。AZ 可能不會用 EUA，緊急狀況已經快結束了，所以今天有新聞傳出會給 EUA 的是 Novavax，AZ 可能會走 full approval，已經做了五六萬人的臨床實驗，可以做正式上市了。 6.Jamie：美國現在算完全開放，英國目標是 21 號，好像說要延後，但還沒宣布，但他們的單日確診比例還是比台灣高，一定要到個位數才能開放嗎，還是條件會調整？ 04b：轉第二期沒有標準，全世界沒有一定的標準。但是在疫苗沒打起來之前，打到三成上下後，多少就可以壓制疫情，在打到三成之前，開開關關的就會如同去年的日本一樣。在病毒已經進到社區的狀況下，一放鬆就會起來，不是什麼時候降回二級，以後就會這樣開開關關，要做好這樣的準備。東京也有自己一套標準，但馬上就發現不適用，要邊做邊摸索。現在不是很特別關心每天要降到多少，而是最終你放鬆了，案例就會回來。 翠翠：案例變少，無症狀還是會有，日本就是這樣，導致最後大家無感。 7.韓國 7/1 開始，完整接種者免隔離，5/5 在境內接種完整疫苗打完第二劑，無論是否本國人都免隔離。在海外接種，入境可申請免隔離，認證的有輝瑞、嬌生、莫德納、AZ、科興、國藥。現在沒有說到混打，但相信之後混打會變成趨勢。美國紐約洛杉磯開放免隔離，日本東京擬定疫苗護照，歐盟開始開放。當先進各國都開放自由入境，台灣政府難道還堅持隔離嗎，就像現在完整接種的飛航人員 反而變回 7+7，這些看起來都不是根據科學的決策。 04b：同意。指揮中心的規劃是國內施打六成以上，才會考慮開放回國不用隔離。但這是原本台灣守的像世外桃源的規劃，但現在還需要堅持這些事嗎？重點是多半的人都打疫苗，各國也是都打到疫苗才開放，重點是什麼時候可以打起來。說明年之後是因為可能那時候才有達到群體免疫，不一定都是國產疫苗。國產如果成功，也有可能量產遇到問題，Novavax 就是量產遇到問題，誰知道我們什麼時候會打到六成。 8.Pauline：李博士有提到台灣是否要先打一劑，還是要把主力人士都打兩劑？英國的疫苗護照已經開始推行，像是球場演唱會，但只有開放 25% 座位，入場的人都要有陰性報告或是 14 天前完整打過兩劑。現在是第三階段解封，還有最後的解封日期，現在還是沒有明確的決定，過幾天會有。 補充：國籍航空機組員打完兩劑，就七天自主管理，不是 7+7，而且每三個月會監測一次，確定有完整保護力。沒有完全接種的才是 7+7 或 5+9。 9.牙醫看診：是否一定要打完第二劑才比較安全？ 04b：牙醫真的是高風險族群，就是製造氣溶膠的場域，建議完整接種完再繼續從事工作，自我防護也很重要。現在都在推企業醫院診所定期快篩，針對員工。很小心的話可以對病人快篩，自費快篩，但是在員工和醫師都有打疫苗後就不用這樣子。 10.請問 AZ 的副作用會跟身體哪些地方不好有關嗎？例如腸胃不好就會出現嘔吐拉肚子？ 04b：我自己有壓力就會頭痛，我打完 AZ 一天後的確就頭痛，但跟原本頭痛等級差不多，沒有特別痛。副作用真的每個人都不一樣，不用想太多，這就是身體產生免疫力的過程，這過程就類似真的感冒得病毒感染，沒什麼大不了，過去後就產生免疫力。因為擔心這個就不打疫苗真的是因噎廢食，進入社區感染後就沒什麼好選，擔心副作用的就不擔心老人家會得病嗎？60 歲以上老人打疫苗發燒的比例不到 7%，真的不用太擔心。 11.請問已經得過無症狀的人再去打疫苗會發生什麼事？ 04b：抗體會衝得很高，身體有免疫記憶，他的第一劑等於別人的第二劑。理想上假如用不要浪費疫苗的觀點，（疫苗不足的情況下）先測抗體，看是否有得過，有可以先不用打，在感染半年左右都先不用打。但美國就沒特別強調，因為很多人無症狀，要釐清到底有沒有感染很麻煩，就全部人都打，因為打 mRNA 產生的中和抗體比自然感染還高，在追蹤自然感染的抗體會越來越下來，就不管有沒有得過都來打。所以有得過的人，打第一針相當於別人第二針，所以第一針會很不舒服，大概可以這樣區別。理論上這種人莫德納打一針就夠了，打第二針也只是增加副作用，抗體衝這麼高也可能會引發其他問題。 12.請問單株抗體有應用在防止轉重症的醫療行為嗎？ 04b：有，上星期有訂出藥物治療會用在哪些人。去年川普選舉前得病，就是有打過這個藥，台灣現在也有買了，有機會用得到。 13.新加玻有優先施打機場人員，打兩劑，因為前陣子爆發的感染，懷疑是機場人員染疫，傳入社區，因為施打疫苗後很多無症狀。院內有九成都打過，算是小型群體免疫，機場也有定期自我採檢，台灣就算打起來，也會有小規模爆發的可能。 CDC 的文件寫說如果是打 FDA、WHO 認證的疫苗，如果要打美國認證的，最短需間隔 28 天，但都說可能。這 28 天應該是沒有理論基礎的，這有關於混打的政策，因為有不同疫苗平台跟資訊，可能要看是混打哪些疫苗，以後資訊會越來越多。 14.每年都會出現皰疹，打疫苗後也會誘發疫苗發作嗎？要先吃藥防範嗎？ 04b：應該不會造成免疫低下，不用擔心。 補充感染過的：法國說有確診過的只會打一劑。 04b：合理政策 已經感染的人在打一劑很快抗體就會衝到很高。 15.請問 25 歲女性打 AZ 有什麼方法可以減輕血栓？ 04b：沒有，但不要吃阿斯匹靈，反而會讓流血問題變嚴重，靜脈血栓阿斯匹靈無法預防，假如吃抗凝血藥劑可以嗎？ 黃醫師：應該沒辦法，其實是要吃類固醇，但吃了疫苗就白打了。真的發生就會吃口服的，會用這類型藥物治療靜脈血栓。 04b：一般人不建議用這個藥預防，應該是有症狀再去驗抗體比較正確。 黃醫師：有症狀再吃，沒症狀吃沒意義。 16.機組員打完兩劑只要七天，是否會擔心破口？ 不擔心，現在國內就是有感染，這次諾富特主要破口不是3+11 出問題的是諾富特的管理，讓外部機師有機會跟其他人接觸，機師都是同一種病， 都是在諾富特被傳染，根本不是 3+11 的問題。 高端 聯亞 國產疫苗懶人包 第二期結束就緊急授權可行嗎？ https://linshibi.com/?p=39547 新冠快篩懶人包 普篩 抗體快篩 抗原快篩 https://linshibi.com/?p=36564 新冠肺炎疫情下的防疫須知 常見問題解答FAQ https://linshibi.com/?p=35408 新冠疫苗常見問題懶人包 https://linshibi.com/?p=38945 林氏璧醫師的電子名片 https://lit.link/linshibi 歡迎贊助我喝咖啡 https://pay.firstory.me/user/linshibi Powered by Firstory Hosting